Exenatide (EXE), the first clinically used GLP-1 receptor agonist (GLP-1RA), is a hypoglycemic agent with novel mechanisms developed in the field of type 2 diabetes mellitus (T2DM) treatment in recent years. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.